Tight control in rheumatoid arthritis improves outcomes

Practitioner

Volumn 253, Issue 1716, 2009, Pages 29-32

  Östör, Andrew J K ^a   Conaghan, Philip G ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; HUMAN; MIDDLE AGED; PATIENT REFERRAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MIDDLE AGED; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 70349580531     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. Rheumatology 2002;41(7):793-800. (Pubitemid 34822963)
2. Symmons DP, Barrett EM, Bankhead CR et al. The incidence of rheumatoid arthritis in the United Kingdom: Results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33(8):735-739. (Pubitemid 24249180)
3. National Institute for Health and Clinical Excellence. Rheumatoid arthritis:The management of rheumatoid arthritis in adults. Clinical guideline 79. London, NICE.2009
4. Combe B, Landewe R et al. EULAR: Recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2007;66:34-45 (Pubitemid 46044858)
5. Goh C, Ostor A. Why do you need to know about cyclic citrullinated peptide. Rheum Pract 2008; 6(2): 8-11
6. Ley R, Conaghan PG. Early diagnosis crucial in polyarthralgia. Practitioner 2007; 251 (1701):17-22
7. Van Der Kooij SM, Goekoop-Ruiterman YP, De Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2008 Jul 28. [Epub ahead of print]
8. National Institute for Health and Clinical Excellence. Rituximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 126. London. NICE. 2007
9. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 130. London. NICE. 2007.
10. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single blind randomised controlled trial Lancet 2004; 364:263-69 (Pubitemid 38942816)